Identification of Antagonistic Action of Pyrrolizidine Alkaloids in Muscarinic Acetylcholine Receptor M1 by Computational Target Prediction Analysis [PDF]
PharmaceuticalsPyrrolizidine alkaloids (PAs) are one of the largest distributed classes of toxins in nature. They have a wide range of toxicity, such as hepatotoxicity, pulmonary toxicity, neuronal toxicity, and carcinogenesis.
Sara Abdalfattah +7 more
doaj +4 more sources
The novel orthosteric agonist M1 muscarinic acetylcholine receptor reveals anti-Alzheimer’s disease activity [PDF]
Scientific ReportsCholinergic treatments with an emphasis on M1 muscarinic acetylcholine receptor (mAChR) agonists as potential modulating agents are a new approach in Alzheimer’s disease (AD) therapy. In previous research, we designed and characterized novel thiazolidine-
Maryam Taheri +2 more
doaj +3 more sources
Muscarinic acetylcholine receptor M1 mediates prostate cancer cell migration and invasion through hedgehog signaling [PDF]
Asian Journal of Andrology, 2018 The autonomic nervous system contributes to prostate cancer proliferation and metastasis. However, the exact molecular mechanism remains unclear. In this study, muscarinic acetylcholine receptor M1 (CHRM1) expression was measured via immunohistochemical ...
Qing-Qing Yin +3 more
doaj +3 more sources
Enhanced muscarinic M1 receptor gene expression in the corpus striatum of streptozotocin-induced diabetic rats [PDF]
Journal of Biomedical Science, 2009 Acetylcholine (ACh), the first neurotransmitter to be identified, regulate the activities of central and peripheral functions through interactions with muscarinic receptors. Changes in muscarinic acetylcholine receptor (mAChR) have been implicated in the
Mathew Jobin +3 more
doaj +4 more sources
Long-Term—But Not Short-Term—Plasticity at the Mossy Fiber–CA3 Pyramidal Cell Synapse in Hippocampus Is Altered in M1/M3 Muscarinic Acetylcholine Receptor Double Knockout Mice [PDF]
Cells, 2023 Muscarinic acetylcholine receptors are well-known for their crucial involvement in hippocampus-dependent learning and memory, but the exact roles of the various receptor subtypes (M1–M5) are still not fully understood.
Fang Zheng +2 more
doaj +2 more sources
Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors [PDF]
Neurobiology of Disease, 2015 Clinical studies demonstrate that scopolamine, a non-selective muscarinic acetylcholine receptor (mAchR) antagonist, produces rapid therapeutic effects in depressed patients, and preclinical studies report that the actions of scopolamine require ...
Andrea Navarria +10 more
doaj +2 more sources
Molecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor [PDF]
, 2014 Background: BQCA is a selective allosteric modulator of the M1 mAChR. Results: Residues that govern BQCA activity were identified using mutagenesis and molecular modelling.
Alaa Abdul‐Ridha +8 more
openalex +5 more sources
Mechanistic Insights into Allosteric Structure-Function Relationships at the M1 Muscarinic Acetylcholine Receptor [PDF]
, 2014 Background: Selective and potent positive allosteric modulators (PAMs) of the M1 mAChR have been recently described. Results: Use of structural analogues and mutagenic mapping identified the mechanistic basis for increased PAM activity.
Alaa Abdul‐Ridha +7 more
openalex +5 more sources
Recovery of hippocampal functions and modulation of muscarinic response by electroacupuncture in young diabetic rats [PDF]
Scientific Reports, 2017 The muscarinic receptor response to acetylcholine regulates the hippocampal-related learning, memory, neural plasticity and the production and processing of the pro-nerve growth factor (proNGF) by hippocampal cells.
Marzia Soligo +9 more
doaj +3 more sources
The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia [PDF]
Frontiers in PsychiatryCognitive impairment is a core symptom of schizophrenia and a major determinant of poor long-term functional outcomes. Despite considerable efforts, we do not yet have any approved pharmacological treatments for cognitive impairment associated with ...
Samantha E. Yohn +4 more
doaj +2 more sources